Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
79%
Numeric claims
2
Consistency
contradicted
Question ledger
Damayanti Kerai · HSBC
evasiveI think if you noted Kiran's commentary, the biosimilars biologics business has performed very strongly in the quarter. Not only has the revenue grown 18% year-on-year, there's also been an improvement in the EBITDA margin.
Damayanti Kerai · HSBC
directThe debt, I think we have said that mainly it's at Biocon Biologics level. We have a net debt of roughly $1.1 billion in June at biosimilars level, approximately $100 million at generics level, and $120 million cash positive in research.
Damayanti Kerai · HSBC
directQ2 will definitely go down for Goldman Sachs, which had the 5% coupon on $180 million. That would go down, as I mentioned. Kotak and Edel will be more later part of this fiscal.
Damayanti Kerai · HSBC
directThis quarter, emerging market is about 23%. Advanced markets is about 77%. On a full-year basis, you should factor 75%-25%, Damayanti. Within 75% of the advanced markets, U.S., the North Am will be 40% +, and the balance will be rough.
Surya Patra · PhillipCapital
directIt's that $1.1 billion. I'll repeat, Biocon Biologics has a net debt of $1.15 billion, $100 million debt in generics, $100 million cash in Syngene.
Surya Patra · PhillipCapital
partialThe impact of all these facilities' operating costs are in the P&L, which is going to be on an ongoing basis. The impact is roughly INR 60 crore a quarter.
Surya Patra · PhillipCapital
directOn a fully diluted basis, assuming all these, I mean, Goldman and Edel is paid out, we'll be up to 78% stake in Biocon Biologics.
Surya Patra · PhillipCapital
directNo, there's no compulsion. I think we have said that IPO is a, I mean, the commitment to Viatris that we had was the best effort. We have time to give exit to investors, which is in a few years. There's no compulsion as such.
Surya Patra · PhillipCapital
partialIt's been a very successful launch led by our U.S. team there. I think one of the key things to bring to your attention is that we've had very strong formulary coverage for this product.
Neha Manpuria · Bank of America
directAs the products continue to transition the Stelara from the payers starting July 1, you're starting to see what Shreehas said, early uptake of ustek. These products will continue to see, we see one full basis point that has contributed to that increase in June.
Neha Manpuria · Bank of America
directDoctors are getting used to writing Yesintek. Remember, interchangeability is not to each biosimilar. It's only to the brand. As the patients and doctors get used to utilizing the Biocon Yesintek, it becomes very sticky.
Neha Manpuria · Bank of America
partialWe believe that the oncology franchise for us in the U.S. has been very, very strong. In fact, we still have over a fourth of the market with the two biosimilars that we've launched, and it continues to be very, very profitable.
